Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TPI headed the wrong way. Will follow for a bottom.
Smitter SMTT
I hope everyone here is smiling as wide as I am this morning. Great results, great guidance, great company!
This stock is going back to $4.00 in a hurry!
Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6
Press Release Source: Tianyin Pharmaceutical Co., Inc. On Monday August 30, 2010, 2:30 pm EDT
CHENGDU, China, Aug. 30 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics will participate in the Roth Fall Conference from September 1 - September 6 at Grand Wailea Resort Hotel, Maui, Hawaii.
Dr. James Jiayuan Tong, Tianyin's Chief Financial Officer, Chief Business & Development Officer and Director is invited to present in two following panel discussions at the conference.
CFO Essentials -- Updates And Practical Implications For CFOs of U.S.-Listed Chinese Companies
Wednesday, September 1, 2:30 pm - 4:00 pm, Haleakala Ballroom China Social Infrastructure Panel Thursday, September 2, 10:00 am - 10:55 am, Haleakala Ballroom
Probably the same reason most stocks have been beat up lately, especially China stocks.
Here is a good write, that has me looking at buy here finally, for the long haul!
http://seekingalpha.com/article/217705-three-undervalued-chinese-dividend-stocks?source=email
Jiangchuan Macrolide Facility Update
http://finance.yahoo.com/news/Jiangchuan-Macrolide-Facility-prnews-4043767532.html?x=0&.v=90
Can someone explain to me how this stock keeps getting crushed? It's trading at a small P/E, has plenty of growth coming, and is even backed by a nice dividend.
Tianyin Pharmaceutical Co., Inc. F3Q10 (Qtr End 03/31/10) Earnings Call Transcript
http://seekingalpha.com/article/205048-tianyin-pharmaceutical-co-inc-f3q10-qtr-end-03-31-10-earnings-call-transcript?source=yahoo
Tianyin Reports Record Third Quarter 2010 Financial Results
Press Release Source: Tianyin Pharmaceutical Co., Inc. On Wednesday May 12, 2010, 12:00 am EDT
CHENGDU, China, May 12 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company that specializes in the modernized traditional Chinese medicine ("TCM") and branded generics today announced fiscal results for its third quarter ended March 31, 2010.
Third quarter fiscal year 2010 ending March 31, 2010 financial highlights -- Q3 FY2010 revenue increased 60% year over year to $15.9 million, net Income Increased 53% to $2.9MM with EPS of $0.11 per share (basic), or $0.09 per share (diluted) -- Cash and cash equivalents were $23.3 million on March 31st, 2010 -- Nine month 2010 Cash Flow from Operations Increased 95% year over year to $8.6 million -- Sichuan Jiangchuan joint venture progress on schedule Q3 FY2010 Results Q3 FY2010 Q3 FY2009 YoY Sales $15.9 million $10.1 million +60% Gross Profit $8.4 million $4.9 million +71% Net Income $2.9 million $1.9 million +53% EPS (Diluted) $0.09 $0.08 +12% Diluted Shares 31.6 million 24.8 million +27% Nine Months FY2010 Results Nine Months Nine Months YoY FY2010 FY2009 Sales $44.3 million $29.6 million +50% Gross Profit $23.2 million $14.9 million +55% Net Income $7.7 million $5.7 million +35% EPS (Diluted) $0.26 $0.23 +13% Diluted shares 29.9 million 24.7 million +21%
Sales for 3Q FY2010 was $15.9 million, up 60.0%, as compared to sales of $9.9 million for 3Q FY2009. Sales for the nine months ended March 31, 2010 were $44.3 million, as compared to total sales of $29.6 million for the nine months ended March 31, 2009, an increase of $14.7 million or 50%. The sales growth was primarily the result of the continuous channel expansion, market penetration and optimized usage of our expanded production facility. We expect greater unit sales as a result of the expansion of both our sales channels and sales force as we continue to implement our sales and marketing strategy.
Revenues from the our top selling products, Ginkgo Mihuan Oral Liquid (GMOL), Apu Shuangxin Oral Liquid (ASOL), Xuelian Chongcao (XLCC) and Azithromycin Dispersible Tablets, were $8.8 million, representing 62.9% of the total quarterly revenue.
Cost of sales for the three months ended March 31, 2010 was $7.5 million or 47% of sales as compared to $5.1 million or 51% of sales for the three months ended March 31, 2009. Cost of sales for the nine months ended March 31, 2010 was $21.0 million or 47.5% of sales as compared to $14.7 million or 50% of sales for the nine months ended March 31, 2009. Our cost of sales consists of the raw material cost, labor, depreciation and amortization of manufacturing equipment and facilities, and other overhead. The improvement of our cost of sales was due to an increase in higher margin products in our sales mix along with enhanced cost control measures that yielded greater efficiencies during the manufacturing process.
Gross margin for the three months ended March 31, 2010 was 53% as compared to 49% for the three months ended March 31, 2009. This was achieved by optimizing portfolio with higher margin products, such as Ginkgo Mihuan Oral Liquid and Apu Shuangxin, while reducing the production of lower margin products, such as Qingrejiedu Oral Liquid and Hugan Tablets.
Operating expenses were $4.8 million for the three months ended March 31, 2010, as compared to $2.6 million for the three months ended March 31, 2009. Operating expenses were $13.7 million for the nine months ended March 31, 2010, as compared to $8.0 million for the nine months ended March 31, 2009, an increase of $5.8 million or 73%. The increase was primarily due to our recent sales and marketing strategy that increased our sales payroll and marketing expenses, along with the increased compensation expenses to external service providers.
Net income was $2.9 million for the three months ended March 31, 2010, as compared to net income of $1.9 million for the three months ended March 31, 2009, an increase of $1.0 million or 53%. Net income was $7.7 million for the nine months ended March 31, 2010, as compared to net income of $5.7 million for the nine months ended March 31, 2009, an increase of $1.9 million or 33%. The net income gain was primarily the result of increase in our revenue along with higher product margins.
Diluted earnings per share for the three months ended March 31, 2010 were $0.09, compared to $0.08 in the same period 2009, based on 31.6 million and 24.8 million shares for 2010 and 2009, respectively.
"Our steadfast efforts in sales expansion, market penetration, new production utilization and portfolio optimization were reflected by another quarter of solid growth in both top and bottom line." stated Dr. Jiang, Guoqing, Tianyin's Chief Executive Officer. "To fuel our future growth, we are continuing the Sichuan Jiangchuan Pharmaceutical Joint Venture (Jiangchuan) to produce macrolide antibiotics, which addresses a large and rapidly growing market in China. Our construction is progressing on schedule and we expect Jiangchuan to contribute to our growth starting fiscal 2011. Our 52 product portfolio featuring patented as well as modernized TCMs and branded generics that target a series of high incidence diseases with addressable billion dollar market. We believe that the favorable health care reform policies, along with growing disposable income, and urbanization of vast agricultural regions remain to be strong growth drivers for China's pharmaceutical market."
Balance Sheet and Cash Flow
As of March 31, 2010, we had cash and cash equivalents of $23.3 million. Net cash generated from operating activities was $8.6 million for the nine months ended March 31, 2010 as compared to $4.4 million for the same period of 2009. The strong cash flow was primarily the result of revenue growth which led to an increased net income. We believe that Tianyin is adequately funded to meet all of our working capital and capital expenditure needs for 2010.
Net cash used in investing activities for the nine months ended March 31, 2010 and 2009 totaled $5.5 million and $5.2 million respectively. The increase was mainly due to our new drugs development and the construction of Jiangchuan production facility.
Business Development & Outlook
Progress update on Sichuan Jiangchuan Pharmaceutical (Jiangchuan):
Since our announcement of the Jiangchuan JV on October 29, 2009 focusing on the production of macrolide antibiotics, such as Azithromycin, one of the world's best-selling antibiotics. Jiangchuan holds a license from China's SFDA to produce macrolide antibiotics and a related business license from the Industry and Commerce Bureau and Tax department. Tianyin owns 77% of the JV and plans to utilize Jiangchuan as the foundation of a broader, longer term strategy to build a significant presence in the rapidly growing macrolide antibiotics market. Construction on a new production facility in Xinjin Industrial Development Area commenced January 8, 2010 with Phase I expected to be operational by August, 2010 and Phase II to be operational by the second half of 2010, with total anticipated capital expenditures of $20 million. Tianyin anticipates the revenue contribution from the initiative starting fiscal 2011.
Fiscal 2010 Guidance
The management reaffirms FY2010 guidance of $63 million and net income of $11 million, representing 48% and 40% year over year growth respectively.
Conference Call
Senior management of Tianyin will host a conference call to discuss its fiscal 2010 third quarter results at 9:00 a.m. ET on Wednesday, May 12, 2010.
Interested parties may access the call by dialing +1-877-941-4776 (U.S.), or +1-480-629-9762 (International). The conference ID is 4297414. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.
A replay will be available through May 26, 2010 and can be accessed by dialing +1-800-406-7325 (U.S.), or +1-303-590-3030 (International), passcode 4297414.
Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
Press Release Source: Tianyin Pharmaceutical Co., Inc. On Friday May 7, 2010, 5:00 pm EDT
CHENGDU, China, May 7 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company that develops, manufactures and sells modernized traditional Chinese medicine ("TCM") and branded generics based in Chengdu, China, today announced that the senior management will host a conference call to discuss its fiscal 2010 third quarter results at 9:00 a.m. ET on Wednesday, May 12, 2010.
Interested parties may access the call by dialing +1-877-941-4776 (U.S.), or +1-480-629-9762 (International). The conference ID is 4297414. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.
A replay will be available through May 26, 2010 and can be accessed by dialing +1-800-406-7325 (U.S.), or +1-303-590-3030 (International), passcode 4297414.
This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=00007515
This event is optimized for Microsoft's Windows media player version 9. To download, please go to http://www.microsoft.com/windows/windowsmedia/download .
Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
Press Release Source: Tianyin Pharmaceutical Co., Inc. On Wednesday April 21, 2010, 9:00 pm EDT
CHENGDU, Sichuan, China, April 21 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI) was invited by Sino American Biopharmaceutical Association (SABPA) to present at its 5th Annual Biomedical Forum held at Irvine, California on April 24th, 2010. SABPA Biomedical forum focuses on innovations in pharmaceutical and biotechnology industries, as well as business opportunities to thrive in the new economy. The forum provides an attractive platform for entrepreneurs, scientists, investors, executives and policy makers to promote life sciences, biotechnology, pharmaceutical, medical devices and alliances across the biomedical industry.
"We appreciate the invitation by SABPA to interface with a large audience of industrial professionals, entrepreneurs and healthcare investment funds," said Dr. James J. Tong, Chief Financial Officer and Chief Business & Development Officer of Tianyin, "Since 2005, SAPBA conferences have been the forefront to bridge biopharmaceuticals and innovations between the healthcare industry of US and China. We look forward to the in-depth interaction with the biopharmaceutical community in US."
Dr. Jiang, Guoqing, Chairman and CEO of Tianyin Pharmaceutical pointed out, "The past 10 years have seen the rapid expansion of China health care industry, propelled by the economic growth in China, favorable government policies and accelerated demands for pharmaceuticals resulted from an increasing urbanization of a growing population. The ongoing healthcare reform provides further momentum for both generic medicines as well as innovative biopharmaceuticals. Tianyin is positioned to explore the opportunities on both fronts."
SAPBA meeting on 24th of April, McDonald Auditorium, University of California, Irvine from 8:30 am till 4:30 pm (http://www.sabpa.org/web/OCLA/)
Can Tianyin Pharmaceutical Heal Your Portfolio?
Tianyin Pharmaceutical Co. (TPI) is a Chinese company offering traditional Chinese medicine as well as more modern and westernized types of medication. This gives the company an advantage, as it increases their potential customer base - as does their mix of prescription/over the counter offerings. TPI is positioned to grow, with 39 drugs in their portfolio and 17 more in the pipeline. Further adding to TPI's strength is the fact that its founder grew a prior pharma company in China to a $1 billion market cap and the company has recently installed an impressive new CFO.
Prior to joining TPI, their new CFO, Dr. James Jiayuan Tong, was the Head of China Healthcare Investment Banking at Roth Capital Partners. Tong lead Roth's successful efforts growing deals in the Chinese healthcare sector. His responsibilities as CFO, CBDO, and board member will help fuel TPI's growth and development. The Chinese healthcare industry is being fueled by current economic growth and healthcare reform in China.
Similarly, founder Dr. Guoqing Jiang is a well-respected industry veteran with over 15 years of extensive experience and a proven track record. Prior to TPI, Dr. Jiang served senior management positions at several pharmaceutical companies including a post as the CEO at Kelun Pharmaceutical Group, which now has a $1B market cap.
Tianyin Pharmaceutical expects to have continued strong growth for the 2010 and 2011 fiscal years. Their revenues could potentially increase to $63.3 million and $113.3 million, respectively, for FY 2010 and 2011, representing an approximate revenue growth of 48% and 79%. During their FY 2010, the company anticipates producing a minimum net income of approximately $10.38 million, which is 30% net income growth, as compared to their FY 2009.
This stock is very alluring to us due to its low price-to-earnings ratio, and in our opinion it’s undervalued with plenty of growth on the horizon. TPI is currently at a $98 million market cap, sitting on $12 million in cash, and is growing 10% quarter over quarter. For these reasons, I believe Tianyin Pharmaceutical is a good value investment and I bought shares at $3.63/$3.64.
Disclosure: Author long TPI
http://seekingalpha.com/article/198745-can-tianyin-pharmaceutical-heal-your-portfolio?source=yahoo
http://www.dailyfinance.com/company/tianyin-pharmaceutical-co-inc/tpi/ase/institutional-ownership
http://www.nasdaq.com/asp/holdings.asp?symbol=TPI&selected=TPI&FormType=Institutional
http://www.secform4.com/insider-trading/1362718.htm
http://www.form4oracle.com/company/tianyin-pharmaceutical-co-inc-tpi/company-transactions?id=12336
Tianyin Pharmaceutical Co., Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
http://seekingalpha.com/article/187395-tianyin-pharmaceutical-co-inc-f2q10-qtr-end-12-31-09-earnings-call-transcript?source=yahoo
Interested in this stock and liking its past earnings reports very much...
3.7 its a conviction buy...
maybe the dilution was the only ugly thing in the report...but did you see the earnings??
the sales??
the growth??
it was just beautiful...awesome results.....the guidance its just great...
3.7 its a buy, buy, buy-----
8:32AM Tianyin Pharma expects operational benefits from the recently published Guide to Reform of Pricing Mechanism of Medicine and Medical Services (TPI) 4.10 : Co announced that it expects operational benefits from the recently published Guide to Reform of Pricing Mechanism of Medicine and Medical Services by the Chinese government. On November 9, 2009, the Chinese National Development and Reform Commission, the Ministry of Health, and the Ministry of Human Resource and Social Security released a comprehensive Guide proposed to protect and foster the development of Chinese Medicine, which is aimed at benefiting the pharmaceutical companies focusing on specialized Chinese medicines like Tianyin Pharmaceuticals. The Guide requires that the pricing of medicine and medical services should reflect the quality differential. As such, the government will support higher sales prices set by the overall market for pharmaceutical companies which develop specialized products with strong efficacy for specific indications. The Guide also defined maximum profit margins for national and local distributors, which will further reduce the overall distribution costs of medicine and improve margins for the producers.
"4.00 nice level to step in."
Before last weeks decline getting tpi @$4 seemed like wishfull thinking unless we have a market correction.
Well last week we had that correction & we probably will have some more follow thru weakness next week as well.
The r/s of tpi was not good during last weeks decline thus I will be watching to see if it holds at the top end of my buy range of $3.68 based on a proven theory of mine.
Theory; On a market correction investors tend to protect profits by selling their biggest winners of the past advance,,,thus buy past market leaders on 30-50% correction from their previous highs.
Since I only expect a 5-10% overall market correction a 30% correction should be closer to the buy point than the more severe 50% drop that should only occur if the markets continue to drop or the fundamentals for tpi are changing.
Today the stock drop to 4.33 and for the people who take the advise to sell in 5 this is a price to begin buying again...
8:00AM Tianyin Pharma receives Chinese SFDA approval for Ofloxacin and Fleroxacin (TPI) 4.99 :
Well..the stock jump in some weeks from 3.2 to almost 5usd...
i think that this is a nice level to take somo profits, and wait a technical resto to 4.1 or 4.2...
at that level we have to buy again
This is potential
with the approval of 2 new drugs, the net income for 2010 is at least 10m so is trading about 10 pe---
but they expect for 2011 a 70% growth.....so with a 2011 forward PE the stock is really cheap at this price.....
i found this a very interesting stock, the only problem i foresee is a posible dilution....
i'm here with you...
nice gain today...
I've been holding TPI for the past several months. What looked like a cup & handle ended up being merely a ladle. However, with tomorrow's NYSE Foreign Companies call there may be some recognition of this profitable, well-funded and heretofore unrecognized company.
No one else besides me following this company?
Graduated from OTCBB to AMEX
10/01/2008 TYNP >>> TPI Tianyin Pharmaceutical Co., Inc. Common Stock N/A N/A
http://www.otcbb.com/dynamic/tradingdata/daily/graduations.htm
NEWS 9/30/08:
Tianyin Pharmaceutical Co., Inc. to Begin Trading on the American Stock Exchange on October 1, 2008
New Ticker 'TPI'
CHENGDU, China, Sept 30, 2008 /Xinhua-PRNewswire-FirstCall via COMTEX/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP - News), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that its common stock will begin trading on the American Stock Exchange (the "AMEX") under the ticker "TPI" at market open on Wednesday, October 1, 2008.
"Moving to the AMEX is a landmark for our Company. We expect that trading on the AMEX will elevate our Company's standing within the international business community, as well as our visibility among the investment community," Dr. Jiang, Chairman and CEO of Tianyin commented. "I would like to thank both Tripoint Capital Advisors, the financial advisor for Tianyin Pharmaceuticals, and CMARK Capital, Tripoint's partner in China, for being instrumental with the transition and activities since our Company became public."
The AMEX Panel's approval is contingent upon the Company being in direct compliance with the Alternative Listing Standards at the time the Company's common shares begin trading on the AMEX, and may be rescinded if the Company is not in compliance with such standards. Once Tianyin's common shares commence trading on the AMEX, the Company will enjoy all of the same privileges and be subject to all of the same regulations as any other company whose shares are listed on the AMEX, regardless of the Listing Standard used to determine the Company's eligibility.
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
132
|
Created
|
09/25/08
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=TPI
Tianyin Pharmaceutical Co., Inc. engages in the development, manufacture, marketing, and sale of modernized traditional Chinese medicines and other pharmaceuticals in the People?s Republic of China. The company?s products are intended to address various medical needs in the therapeutic areas spanning internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology, and pediatrics. It manufactures a portfolio of 39 modernized traditional Chinese medicines and pharmaceuticals, and has a pipeline of 17 products, which are pending regulatory approvals with the China State Food and Drug Administration. The company was founded in 1994 and is based in Chengdu, the People?s Republic of China.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |